These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18316572)

  • 1. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.
    Black PC; Brown GA; Inamoto T; Shrader M; Arora A; Siefker-Radtke AO; Adam L; Theodorescu D; Wu X; Munsell MF; Bar-Eli M; McConkey DJ; Dinney CP
    Clin Cancer Res; 2008 Mar; 14(5):1478-86. PubMed ID: 18316572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer.
    Black PC; Brown GA; Dinney CP; Kassouf W; Inamoto T; Arora A; Gallagher D; Munsell MF; Bar-Eli M; McConkey DJ; Adam L
    J Urol; 2011 Feb; 185(2):693-700. PubMed ID: 21168861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
    Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors.
    Baumgart E; Cohen MS; Silva Neto B; Jacobs MA; Wotkowicz C; Rieger-Christ KM; Biolo A; Zeheb R; Loda M; Libertino JA; Summerhayes IC
    Clin Cancer Res; 2007 Mar; 13(6):1685-94. PubMed ID: 17363521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance.
    Krumbach R; Schüler J; Hofmann M; Giesemann T; Fiebig HH; Beckers T
    Eur J Cancer; 2011 May; 47(8):1231-43. PubMed ID: 21273060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
    Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary-derived growth inhibitor alters traffic of EGFR and induces a novel form of cetuximab resistance.
    Nevo J; Mattila E; Pellinen T; Yamamoto DL; Sara H; Iljin K; Kallioniemi O; Bono P; Heikkilä P; Joensuu H; Wärri A; Ivaska J
    Clin Cancer Res; 2009 Nov; 15(21):6570-81. PubMed ID: 19825952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
    Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
    Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.
    Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G
    Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
    Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.
    Wang X; Zhang S; MacLennan GT; Eble JN; Lopez-Beltran A; Yang XJ; Pan CX; Zhou H; Montironi R; Cheng L
    Clin Cancer Res; 2007 Feb; 13(3):953-7. PubMed ID: 17289890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
    Lu Y; Liu P; Van den Bergh F; Zellmer V; James M; Wen W; Grubbs CJ; Lubet RA; You M
    Cancer Prev Res (Phila); 2012 Feb; 5(2):248-59. PubMed ID: 21982874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
    J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.
    Mrhalova M; Plzak J; Betka J; Kodet R
    Neoplasma; 2005; 52(4):338-43. PubMed ID: 16059652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.
    Perrotte P; Matsumoto T; Inoue K; Kuniyasu H; Eve BY; Hicklin DJ; Radinsky R; Dinney CP
    Clin Cancer Res; 1999 Feb; 5(2):257-65. PubMed ID: 10037173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.